This month, an FDA panel voted to reject MDMA assisted psychotherapy for PTSD. That doesn’t mean the case is closed. The panel is an independent group of 11 scientists, clinicians, and patient advocates who advise the FDA. The FDA will make their final decision in August, and while there’s still a chance for approval we are not optimistic. 90% of the panel members voted against it, and the agency usually follows their advice.
